Patient preferences and willingness to pay for different options of anticoagulant therapy

Marco Moia1, Lorenzo Giovanni Mantovani, Monica Carpenedo

  • 1Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Ca' Granda Maggiore Policlinico Hospital Foundation, Via Pace 9, 20122, Milan, Italy.

Insights

Patients value convenience and safety in new anticoagulant drugs, showing a willingness to pay for features like oral administration and reduced monitoring. Preferences vary based on therapy status and patient demographics, guiding future treatment development.

Area of Science:

  • Pharmacoeconomics
  • Patient-centered care
  • Anticoagulation therapy

Background:

  • Novel oral anticoagulants (NOACs) are emerging as alternatives to vitamin K antagonists.
  • Patient preferences are crucial for developing effective new therapeutic strategies.
  • Understanding patient willingness to pay (WTP) can inform healthcare planning.

Purpose of the Study:

  • To elicit patient preferences for different oral anticoagulant treatment characteristics.
  • To estimate patient willingness to pay for various attributes of anticoagulant therapy.
  • To analyze how patient characteristics influence treatment preferences.

Main Methods:

  • A Discrete Choice Experiment (DCE) was administered to 255 patients at an anticoagulation clinic.
  • Patients evaluated six treatment characteristics: administration route/frequency, monitoring, bleeding risk, interaction attention, dose adjustment, and cost.
  • Statistical analysis explored relationships between patient demographics and preferences.

Main Results:

  • All analyzed characteristics were significant except attention for drug/food interactions and dose adjustment.
  • Patients showed a significant WTP for oral tablets over injections (79/month), once-daily over twice-daily dosing (41/month), reduced bleeding risk (25/month), and less frequent monitoring (20/month).
  • Stable patients prioritized interaction attention; younger/working patients prioritized reduced monitoring frequency.

Conclusions:

  • Patient preferences significantly influence the perceived value of anticoagulant therapies.
  • DCE is a valuable method for quantifying patient preferences and WTP in anticoagulation.
  • Findings provide essential data for optimizing healthcare planning and developing patient-centered anticoagulant strategies.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...